Kotaro Shide

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2416549/publications.pdf

Version: 2024-02-01

93 papers	2,496 citations	361413 20 h-index	206112 48 g-index

102 all docs	102 docs citations	102 times ranked	4478 citing authors

#	Article	IF	Citations
1	Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood, 2022, 139, 967-982.	1.4	44
2	Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly. Tohoku Journal of Experimental Medicine, 2022, 256, 119-125.	1.2	1
3	Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma. Viruses, 2022, 14, 710.	3.3	2
4	Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma. Experimental Hematology, 2022, 111, 41-49.	0.4	0
5	Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. Haematologica, 2021, 106, 532-542.	3.5	9
6	Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia, 2021, 35, 454-467.	7.2	27
7	Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult Tâ€cell leukemia/lymphoma. European Journal of Haematology, 2021, 106, 398-407.	2.2	6
8	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discovery, 2021, 2, 450-467.	5.0	10
9	Fibrocytes in primary myelofibrosis. Oncotarget, 2021, 12, 2101-2103.	1.8	0
10	Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan. Journal of Clinical Medicine, 2021, 10, 105.	2.4	5
11	Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nature Communications, 2021, 12, 6177.	12.8	30
12	Calreticulin mutations in myeloproliferative neoplasms. International Review of Cell and Molecular Biology, 2021, 365, 179-226.	3.2	6
13	The role of driver mutations in myeloproliferative neoplasms: insights from mouse models. International Journal of Hematology, 2020, 111, 206-216.	1.6	7
14	TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. BMC Cancer, 2020, 20, 5.	2.6	16
15	Abstract 12873: Clonal Hematopoiesis With JAK2V617F Promotes Pulmonary Hypertension Through ALK1. Circulation, 2020, 142, .	1.6	1
16	JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review. Leukemia Research Reports, 2020, 13, 100194.	0.4	0
17	Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. Blood, 2020, 136, 106-118.	1.4	10
18	CARD11 Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ. Blood, 2020, 136, 17-18.	1.4	1

#	Article	IF	Citations
19	Dissecting Multicellular Ecosystems of HTLV-1 Infection and ATL By Multi-Omics Single Cell Analysis. Blood, 2020, 136, 18-18.	1.4	0
20	Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas. Blood, 2020, 136, 3-4.	1.4	1
21	Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma. Blood, 2020, 136, 29-30.	1.4	0
22	Essential thrombocytosis attributed to JAK2-T875N germline mutation. International Journal of Hematology, 2019, 110, 584-590.	1.6	11
23	Vitamin D receptorâ€“mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. Blood, 2019, 133, 1619-1629.	1.4	21
24	Monocyte-derived fibrocytes elimination had little contribution on liver fibrosis. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 348-353.	1.3	3
25	Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis. Blood Cancer Journal, 2019, 9, 42.	6.2	15
26	Depletion of Neoplastic CD11b Positive Cells in Jak2V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis. Blood, 2019, 134, 310-310.	1.4	0
27	The Role of Calreticulin in Normal Hematopoiesis and Neoplastic Hematopoiesis of Myeloproliferative Neoplasms. Blood, 2019, 134, 309-309.	1.4	0
28	Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. International Journal of Hematology, 2018, 107, 681-688.	1.6	13
29	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	1.4	124
30	Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia. International Journal of Hematology, 2018, 108, 411-415.	1.6	14
31	Outcome of allogeneic hematopoietic cell transplantation in patients with adult <scp>T</scp>â€cell leukemia. Hematological Oncology, 2018, 36, 651-655.	1.7	7
32	Haploinsufficiency of CALR Confers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the Calr Mutation. Blood, 2018, 132, 97-97.	1.4	2
33	TET2 Mutation Associated with Organ Infiltrations in ATLL. Blood, 2018, 132, 1345-1345.	1.4	0
34	Effects of mogamulizumab in adult Tâ€cell leukemia/lymphoma in clinical practice. European Journal of Haematology, 2017, 98, 501-507.	2.2	14
35	Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia, 2017, 31, 1136-1144.	7.2	62
36	Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Advances, 2017, 1, 1001-1015.	5.2	16

#	Article	IF	Citations
37	<i>TET2</i> mutation in diffuse large B-cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 56, 145-149.	0.8	16
38	Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations. Annals of Laboratory Medicine, 2017, 37, 159-161.	2.5	1
39	Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. Anticancer Research, 2017, 37, 3841-3847.	1.1	1
40	Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World Journal of Hepatology, 2017, 9, 1340-1345.	2.0	8
41	Mutant calreticulin causes essential thrombocythemia. Oncotarget, 2017, 8, 88251-88252.	1.8	0
42	Aberrant PD-L1 expression through 3â€²-UTR disruption in multiple cancers. Nature, 2016, 534, 402-406.	27.8	536
43	Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. International Journal of Hematology, 2016, 103, 423-428.	1.6	8
44	Mogamulizumab for ATLL in Clinical Practice. Blood, 2016, 128, 2998-2998.	1.4	1
45	HMGA2 Orchestrates the Tumorgenesis of Myeloproliferative Neoplasms (MPN) in Corporation with JAK2V617F. Blood, 2016, 128, 796-796.	1.4	0
46	Physiological Expression of Calr Mutant Increases Cell Growth and Cytokine Independency in Human Cell Lines Expressing Mpl, and Develops Essential Thrombocythemia in Mice. Blood, 2016, 128, 954-954.	1.4	0
47	Nasopharyngeal Carcinoma with Bone Marrow Metastasis: Positive Response to Weekly Paclitaxel Chemotherapy. Internal Medicine, 2015, 54, 1455-1459.	0.7	4
48	Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood, 2015, 125, 304-315.	1.4	67
49	TET2 Mutation in Adult T-Cell Leukemia/Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2015, 55, 145-149.	0.8	19
50	Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms. Genomics Data, 2015, 4, 102-108.	1.3	4
51	Integrated molecular analysis of adult T cell leukemia/lymphoma. Nature Genetics, 2015, 47, 1304-1315.	21.4	659
52	Frequent Activating Somatic Alterations in T-Cell Receptor / NF-Îºb Signaling in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 113-113.	1.4	7
53	Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 3882-3882.	1.4	0
54	Expression of HMGA2 Collaborates with JAK2V617F to Progress Myeloproliferative Neoplasms. Blood, 2015, 126, 482-482.	1.4	0

#	Article	IF	Citations
55	Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer Journal, 2014, 4, e174-e174.	6.2	24
56	Therapies Targeting the MAPK Pathway Improve Bone Marrow (BM) Fibrosis Induced By JAK2V617F. Blood, 2014, 124, 162-162.	1.4	1
57	Landscape of Genetic Alterations in Adult T-Cell Leukemia/Lymphoma. Blood, 2014, 124, 75-75.	1.4	1
58	NS-018, a Selective JAK2V617F Inhibitor, Improves JAK2V617F-Induced Murine Myelofibrosis Without Decreasing The Erythrocyte Or Platelet Count. Blood, 2013, 122, 3847-3847.	1.4	2
59	Impact Of TET2 Deficiency On MPN Harboring JAK2V617F Mutation. Blood, 2013, 122, 478-478.	1.4	0
60	Î±SMA+ Macrophages Skewed From Hematopoietic Stem Cells By Vitamin D3 Initiate Myelofibrosis and Subsequent Osteosclerosis. Blood, 2013, 122, 340-340.	1.4	0
61	Ezh2 Loss Accelerates JAK2V617F-Driven Primary Myelofibrosis. Blood, 2013, 122, 110-110.	1.4	0
62	Prognostic Factor, Including Relative Dose Intensity, For Adult T-Cell Leukemia/Lymphoma In Clinical Practice. Blood, 2013, 122, 1799-1799.	1.4	0
63	Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture. International Journal of Clinical Oncology, 2012, 17, 336-340.	2.2	6
64	Elevated HIF-1Î± expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leukemia Research, 2012, 36, e122-e124.	0.8	34
65	Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan. International Journal of Hematology, 2012, 96, 342-349.	1.6	7
66	Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation. Annals of Hematology, 2012, 91, 1633-1643.	1.8	14
67	TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia, 2012, 26, 2216-2223.	7.2	73
68	R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood, 2011, 117, 6866-6875.	1.4	23
69	Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e29-e29.	6.2	38
70	TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation. Blood, 2011, 118, 2471-2471.	1.4	0
71	Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. International Journal of Hematology, 2010, 92, 320-325.	1.6	18
72	JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. British Journal of Haematology, 2010, 150, 334-344.	2.5	46

#	Article	IF	Citations
73	Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions. Biochemical and Biophysical Research Communications, 2010, 400, 252-257.	2.1	12
74	NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant. Blood, 2010, 116, 4106-4106.	1.4	5
75	Preferential Inhibition of An Activated Form of Janus Kinase 2 (JAK2) by a Novel JAK2 Inhibitor, NS-018. Blood, 2010, 116, 4107-4107.	1.4	4
76	Potentiated Activation of VLA-4 and VLA-5 Accelerates Proplatelet-Like Formation In Megakaryocytes.. Blood, 2010, 116, 2585-2585.	1.4	0
77	The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. European Journal of Haematology, 2009, 83, 328-333.	2.2	27
78	p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. Biochemical and Biophysical Research Communications, 2009, 383, 411-416.	2.1	23
79	Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.. Blood, 2009, 114, 3897-3897.	1.4	3
80	JAK2V617F Mutation Selectively Exerts the STAT3 Pathway for Enhancing a Neutrophil Activation Marker.. Blood, 2009, 114, 1901-1901.	1.4	0
81	Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma.. Blood, 2009, 114, 1921-1921.	1.4	0
82	Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia, 2008, 22, 87-95.	7.2	158
83	Elevated Leukocyte Alkaline Phosphatase Scores Induced by Jak2 V617F Mutation. Blood, 2008, 112, 5244-5244.	1.4	0
84	Chronic thrombopoietin overexpression induces mesangioproliferative glomerulopathy in mice. American Journal of Hematology, 2007, 82, 802-806.	4.1	6
85	Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leukemia Research, 2007, 31, 1077-1084.	0.8	10
86	The Effect of Anabolic Steroids on Anemia in Myelofibrosis with Myeloid Metaplasia: Retrospective Analysis of 39 Patients in Japan. International Journal of Hematology, 2007, 85, 338-343.	1.6	36
87	Expression of V617F JAK2 in Mice Leads to MPD Mimicking Human ET, Idiopahtic Myelofibrosis, and PV.. Blood, 2007, 110, 2531-2531.	1.4	0
88	Tyrosine Kinase 2 (Tyk2) Interacts with and Phosphorylates Siva-1, and Auguments the Apoptotic Effect Induced by Siva-1.. Blood, 2006, 108, 1726-1726.	1.4	0
89	Tyk2 Mutation Homologous to V617F Jak2 Is Not Found in Essential Thrombocythaemia, Although It Induces Constitutive Signaling and Growth Factor Independence.. Blood, 2006, 108, 4888-4888.	1.4	0
90	Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leukemia Research, 2005, 29, 761-769.	0.8	53

#	Article	IF	Citations
91	A Novel Mutation in the Juxtamembrane Intracellular Sequence of the Granulocyte Colony-Stimulating Factor (G-CSF) Receptor Gene in a Patient with Severe Congenital Neutropenia Augments G-CSF Proliferation Activity but Not through the MAP Kinase Cascade. International Journal of Hematology, 2005, 82, 28-34.	1.6	6
92	Signal Transducers and Activators of Transcription 3 Augments the Transcriptional Activity of CCAAT/Enhancer-binding Protein Î± in Granulocyte Colony-stimulating Factor Signaling Pathway. Journal of Biological Chemistry, 2005, 280, 12621-12629.	3.4	48
93	Dynamics of Epstein-Barr virus load in pyothorax-associated lymphoma. Journal of Medical Virology, 2003, 70, 137-140.	5.0	8